Eliaz Therapeutics Awarded $ 1.7 Million by NIH for XGAL3’s Apheresis Massive Animal Security Examine

Eliaz Therapeutics Awarded $ 1.7 Million by NIH for XGAL3’s Apheresis Massive Animal Security Examine

SANTA ROSA, California, June 23, 2022 / PRNewswire / – Eliaz Therapeutics Inc (ETI), a therapeutic apheresis firm, was awarded its second NIH grant, an SBIR Section 2 grant for $ 1.7 million. ETI has developed a singular, patented medical system for eradicating Galectin-3 (Gal-3) from human blood. XGAL3® removes each certain and free Gal-3 … Read more

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.